trial

Study of Preladenant for the Treatment of Antipsychotic Induced Movement Disorders in Participants With Schizophrenia (Study P04628)

NCTId NCT00686699
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Terminated
Enrollment 11 (actual)
Sponsored by Merck Sharp & Dohme LLC
Primary completion 2008-03-06
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Terminated
Enrollment
11 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Quadruple
Start
2006-07-10
Primary completion
2008-03-06
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Preladenant

Sponsors

Merck Sharp & Dohme LLCLead Sponsor

Sites

0 total

Linked catalysts

1
Study of Preladenant for the Treatment of Antipsychotic Induced Movement Disorde — primary completion2008-03-06

Facts & assertions

4 sourced
Enrollment
11
Phase
PHASE2
Primary Completion Date
2008-03-06
Status
TERMINATED
relationships
The graph out of here
drug
Preladenant
drug
lead_sponsor
Merck Sharp & Dohme LLC
company
indication
Parkinsonian Disorders
indication
Akathisia, Drug-Induced
indication
Dyskinesia, Drug-Induced
indication